Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Calithera Biosciences	ObsEva	SCYNEXIS	Marker Therapeutics	Enlivex Therapeutics
Symbol	NASDAQ:CALA	NASDAQ:OBSV	NASDAQ:SCYX	NASDAQ:MRKR	NASDAQ:ENLV
Price Information
Current Price	$2.09	$2.80	$6.87	$2.35	$10.04
52 Week Range	Buy	Hold	Buy	Buy	Buy
MarketRank™
Overall Score	1.8	1.4	1.4	1.5	1.4
Analysis Score	3.4	3.2	3.5	3.4	3.5
Community Score	2.8	2.3	2.8	2.5	3.4
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	0.8	0.8	1.7	0.0
Earnings & Valuation Score	1.3	0.6	0.0	0.0	0.0
Analyst Ratings
Consensus Recommendation	Buy	Hold	Buy	Buy	Buy
Consensus Price Target	$5.20	$11.80	$30.29	$8.67	$33.00
% Upside from Price Target	148.80% upside	321.43% upside	340.84% upside	268.79% upside	228.69% upside
Trade Information
Market Cap	$154.76 million	$161.15 million	$141.74 million	$186.36 million	$158.23 million
Beta	1.77	0.99	2.16	1.27	1.14
Average Volume	1,435,902	4,695,241	567,668	2,899,517	366,256
Sales & Book Value
Annual Revenue	$22.25 million	N/A	$120,000.00	$210,000.00	N/A
Price / Sales	6.96	N/A	1,181.12	887.44	N/A
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$2.24 per share	$1.01 per share	$1.32 per share	$0.96 per share	$1.09 per share
Price / Book	0.93	N/A	5.20	2.45	N/A
Profitability
Net Income	$-89,860,000.00	$-108,790,000.00	$-53,710,000.00	$-21,430,000.00	$-9,380,000.00
EPS	($1.90)	($2.49)	($8.10)	($0.47)	($1.11)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	N/A	N/A	N/A
Return on Equity (ROE)	-66.64%	-256.23%	-330.82%	-68.00%	-34.60%
Return on Assets (ROA)	-56.60%	-93.21%	-64.53%	-54.26%	-28.47%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	1.14%	1.39%	N/A	0.02%
Current Ratio	7.07%	2.06%	3.89%	5.03%	7.23%
Quick Ratio	7.07%	2.06%	3.89%	5.03%	7.23%
Ownership Information
Institutional Ownership Percentage	73.99%	52.74%	36.92%	29.42%	2.39%
Insider Ownership Percentage	11.90%	N/A	4.06%	30.90%	N/A
Miscellaneous
Employees	92	42	38	44	36
Shares Outstanding	74.05 million	57.55 million	20.63 million	79.30 million	15.76 million
Next Earnings Date	8/9/2021 (Estimated)	8/5/2021 (Estimated)	5/10/2021 (Estimated)	5/12/2021 (Confirmed)	5/17/2021 (Estimated)
Optionable	Optionable	Not Optionable	Optionable	Optionable	Not Optionable

Source	Headline
	Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Down 18.8% in April americanbankingnews.com - May 3 at 12:46 PM
	Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Expected to Post Earnings of -$0.21 Per Share americanbankingnews.com - May 2 at 12:10 PM
	Enlivex Therapeutics shares are trading higher. Not seeing any company-specific news to justify the price action in the low-float stock. benzinga.com - April 30 at 6:40 PM
	Enlivex Therapeutics Ltd (ENLV) investing.com - April 28 at 8:17 AM
	Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Sees Significant Drop in Short Interest americanbankingnews.com - April 19 at 1:14 AM
	Zacks: Brokerages Expect Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Will Post Earnings of -$0.21 Per Share americanbankingnews.com - April 15 at 2:20 PM
	ENLV May 2021 10.000 call ca.finance.yahoo.com - March 29 at 7:20 PM
	ENLV Aug 2021 15.000 put ca.finance.yahoo.com - March 29 at 2:17 PM
	Enlivex To Study Allocetra Combined With Checkpoint Inhibitors In Solid Tumor Settings benzinga.com - March 23 at 3:18 PM
	Enlivex Announces Research Collaboration with Yale Cancer Center to Assess Synergistic Effect ... apnews.com - March 23 at 4:47 AM
	Enlivex Therapeutics Ltd. (ENLV.TA) sg.finance.yahoo.com - March 22 at 1:45 PM
	Enlivex Announces Research Collaboration with Yale Cancer Center to Assess Synergistic Effect of Allocetra™ in Combination with Immune Checkpoint Inhibitors finance.yahoo.com - March 22 at 8:45 AM
	Enlivex Announces Upcoming Virtual Investor Conference Participations apnews.com - March 10 at 9:04 AM
	Enlivex Announces Upcoming Virtual Investor Conference Participations finance.yahoo.com - March 9 at 8:51 AM
	Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the use of Allocetra in Combination with CAR-T Therapies finance.yahoo.com - March 8 at 9:09 AM
	Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of ... apnews.com - March 2 at 9:05 AM
	Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors finance.yahoo.com - March 1 at 8:56 AM
	Enlivex Therapeutrics receives Chinese patent for Allocetra immunotherapy pharmabiz.com - February 24 at 8:04 PM
	Enlivex Receives Notice of Allowance for Chinese Patent Application Covering Allocetra Immunotherapy wallstreet-online.de - February 22 at 2:47 PM
	Enlivex Announces Exercise of Underwriter's Option to Purchase Additional Shares benzinga.com - February 19 at 8:05 AM
	Enlivex Announces Exercise of Underwriter’s Option to Purchase Additional Shares finance.yahoo.com - February 18 at 9:53 AM
	Enlivex Announces Issuance of New U.S. Patent Covering Methods of Treating Gout, Inflammatory ... apnews.com - February 17 at 8:24 AM
	Enlivex Announces Issuance of New U.S. Patent Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, Ulcerative Colitis and GvHD Using Allocetra Immunotherapy finance.yahoo.com - February 16 at 9:29 AM
	Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 ... apnews.com - February 13 at 12:13 AM
	Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares finance.yahoo.com - February 12 at 7:12 PM

Date	Company	Brokerage	Action
1/5/2021	Calithera Biosciences	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Lower Price Target
1/5/2021	Calithera Biosciences	Smith Barney Citigroup	Lower Price Target
1/5/2021	Calithera Biosciences	HC Wainwright	Lower Price Target
1/5/2021	Calithera Biosciences	SVB Leerink	Downgrade
6/2/2020	Calithera Biosciences	William Blair	Reiterated Rating
3/27/2020	Calithera Biosciences	Jefferies Financial Group	Initiated Coverage
1/12/2021	ObsEva	Wedbush	Reiterated Rating
11/9/2020	ObsEva	JPMorgan Chase & Co.	Downgrade
7/6/2020	ObsEva	BMO Capital Markets	Downgrade
12/10/2019	ObsEva	Royal Bank of Canada	Boost Price Target
11/8/2019	ObsEva	Credit Suisse Group	Downgrade
4/19/2021	SCYNEXIS	Aegis	Lower Price Target
2/17/2021	SCYNEXIS	Maxim Group	Boost Price Target
1/22/2021	SCYNEXIS	Guggenheim	Initiated Coverage
1/5/2021	SCYNEXIS	Cantor Fitzgerald	Initiated Coverage
8/11/2020	SCYNEXIS	LADENBURG THALM/SH SH	Reiterated Rating
8/10/2020	SCYNEXIS	Needham & Company LLC	Initiated Coverage
3/31/2021	Marker Therapeutics	Piper Sandler	Initiated Coverage
3/9/2021	Marker Therapeutics	Oppenheimer	Reiterated Rating
6/24/2020	Marker Therapeutics	Roth Capital	Reiterated Rating
6/24/2020	Marker Therapeutics	Janney Montgomery Scott	Reiterated Rating
6/24/2020	Marker Therapeutics	Nomura	Reiterated Rating
11/13/2019	Marker Therapeutics	Piper Jaffray Companies	Lower Price Target
8/13/2019	Marker Therapeutics	Nomura Securities	Reiterated Rating
3/29/2019	Marker Therapeutics	WBB Securities	Upgrade

(Data available from 5/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources